CD274 and neoplasm: They include, among others, PD-L1 expression in the case of PD-1/PD-L1 targeted agents, tumor mutational burden (TMB), neoantigen load, microsatellite instability, antigen presentation deficiencies, tumor infiltration by immune cells, and immune-related gene expression in tumors [1,2,3,4,5,6,7].